Literature DB >> 29566831

The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value.

Steven D Pearson1.   

Abstract

What should be the relationship between the concepts of cost effectiveness and affordability in value assessments for health care interventions? This question has received greater attention in recent years given increasing financial pressures on health systems, leading to different views on how assessment reports and decision-making processes can provide the best structure for considering both elements. In the United States, the advent of explicit value frameworks to guide drug assessments has also focused attention on this issue, driven in part by the prominent inclusion of affordability within the value framework used to guide reports from the Institute for Clinical and Economic Review. After providing a formal definition of affordability for health care systems, this article argues that, even after using empirical estimates of true health system opportunity cost, cost-effectiveness thresholds cannot by themselves be set in a way that subsumes questions about short-term affordability. The article then presents an analysis of different approaches to integrating cost effectiveness and budget impact assessments within information to guide decision making. The evolution and experience with the Institute for Clinical and Economic Review value framework are highlighted, providing lessons learned and guiding principles for future efforts to bring measures of affordability within the scope of value assessment.
Copyright © 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  affordability; budget impact analysis; cost-effectiveness analysis thresholds; drug pricing

Mesh:

Year:  2018        PMID: 29566831     DOI: 10.1016/j.jval.2017.12.017

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  14 in total

1.  Insurance coverage does not predict outcomes of genetic testing: The search for meaning in payer decisions for germline cancer tests.

Authors:  Laura M Amendola; M Ragan Hart; Robin L Bennett; Martha Horike-Pyne; Michael Dorschner; Brian Shirts; Gail P Jarvik
Journal:  J Genet Couns       Date:  2019-07-17       Impact factor: 2.537

2.  Cancer-Related Care Costs and Employment Disruption: Recommendations to Reduce Patient Economic Burden as Part of Cancer Care Delivery.

Authors:  Janet S de Moor; Courtney P Williams; Victoria S Blinder
Journal:  J Natl Cancer Inst Monogr       Date:  2022-07-05

3.  Critical Reflections on Reimbursement and Access of Advanced Therapies.

Authors:  Steven Simoens; Katrien De Groote; Cornelis Boersma
Journal:  Front Pharmacol       Date:  2022-05-18       Impact factor: 5.988

4.  Analysis of Stakeholder Engagement in the Public Comments of ICER Draft Evidence Reports.

Authors:  Jean A Gerlach; Brian Snow; Katherine M Prioli; Ronald Vertsman; Julie Patterson; Laura T Pizzi
Journal:  Am Health Drug Benefits       Date:  2020-09

5.  Complicated legacies: The human genome at 20.

Authors:  Kathryn Maxson Jones; Robert Cook-Deegan; Charles N Rotimi; Shawneequa L Callier; Amy R Bentley; Hallam Stevens; Kathryn A Phillips; Jeroen P Jansen; Christopher F Weyant; Dorothy E Roberts; Dina Zielinski; Yaniv Erlich; Nanibaa' A Garrison; Stephanie Russo Carroll; Pilar N Ossorio; Yves Moreau; Maya Wang
Journal:  Science       Date:  2021-02-04       Impact factor: 63.714

6.  The insurability of innovative pharmaceutical cancer technologies.

Authors:  Shuli Brammli Greenberg; Einat Dotan; Rachel Arazi
Journal:  Isr J Health Policy Res       Date:  2020-12-21

Review 7.  Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review.

Authors:  Khadidja Abdallah; Isabelle Huys; Kathleen Claes; Steven Simoens
Journal:  Front Pharmacol       Date:  2021-04-21       Impact factor: 5.810

Review 8.  Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations.

Authors:  Matthew Franklin; James Lomas; Gerry Richardson
Journal:  Pharmacoeconomics       Date:  2020-07       Impact factor: 4.981

9.  Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis.

Authors:  Donger Zhang; Xia Li; Jing Ding; Xiatong Ke; Wenpei Ding; Yinan Ren; He Xu; Hongchao Li; Aixia Ma; Wenxi Tang
Journal:  Front Public Health       Date:  2021-07-06

Review 10.  Health Technology Assessment Process for Oncology Drugs: Impact of CADTH Changes on Public Payer Reimbursement Recommendations.

Authors:  Louise Binder; Majd Ghadban; Christina Sit; Kathleen Barnard
Journal:  Curr Oncol       Date:  2022-03-01       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.